Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Lankenau Cancer Center at Lankenau Hospital
mi
from
Wynnewood, PA
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Lankenau Cancer Center at Lankenau Hospital
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Sentara Cancer Institute at Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Sentara Cancer Institute at Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
St. Joseph Cancer Center
mi
from
Bellingham, WA
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
St. Joseph Cancer Center
mi
from
Bellingham, WA
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
CCOP - Kansas City
mi
from
Prairie Village, KA
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
CCOP - Kansas City
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Butterworth Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Butterworth Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
William Beaumont Hospital - Royal Oak Campus
mi
from
Royal Oak, MI
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
William Beaumont Hospital - Royal Oak Campus
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Cooper CyberKnife Center
mi
from
Mount Laurel, NJ
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Cooper CyberKnife Center
mi
from
Mount Laurel, NJ
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Princess Margaret Hospital
mi
from
Toronto,
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Princess Margaret Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated:  3/22/2018
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients
Status: Enrolling
Updated: 3/22/2018
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Click here to add this to my saved trials
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
A Phase II Study of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  3/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
A Phase II Study of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 3/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
A Phase I/II Study of Ganetespib in Combination With Doxorubicin in Solid Tumors (Phase I) and Refractory Small Cell Lung Cancer (Safety Dose Expansion, Phase II)
Status: Enrolling
Updated:  3/22/2018
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
A Phase I/II Study of Ganetespib in Combination With Doxorubicin in Solid Tumors (Phase I) and Refractory Small Cell Lung Cancer (Safety Dose Expansion, Phase II)
Status: Enrolling
Updated: 3/22/2018
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
City of Hope National Medical Center
mi
from
Duarte, CA
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
UC San Diego Medical Center - La Jolla (Thornton Hospital)
mi
from
La Jolla, CA
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
UC San Diego Medical Center - La Jolla (Thornton Hospital)
mi
from
La Jolla, CA
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
University of California San Diego, Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
UC San Diego Medical Center - Hillcrest
mi
from
San Diego, CA
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
UC San Diego Medical Center - Hillcrest
mi
from
San Diego, CA
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
Emory University Hospital Midtown
mi
from
Atlanta, GA
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
Emory University Hospital
mi
from
Atlanta, GA
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
The Emory Clinic
mi
from
Atlanta, GA
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
Swedish Cancer Institute
mi
from
Seattle, WA
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
University of Alabama at Birmingham, IDS Pharmacy
mi
from
Birmingham, AL
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
University of Alabama at Birmingham, IDS Pharmacy
mi
from
Birmingham, AL
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
UC San Diego Moores Cancer Center - Investigational Drug Services
mi
from
La Jolla, CA
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
UC San Diego Moores Cancer Center - Investigational Drug Services
mi
from
La Jolla, CA
Click here to add this to my saved trials
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated:  3/22/2018
Swedish Investigational Drug Services Pharmacy
mi
from
Seattle, WA
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer
Status: Enrolling
Updated: 3/22/2018
Swedish Investigational Drug Services Pharmacy
mi
from
Seattle, WA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Lucille P. Markey Cancer Center at University of Kentucky
mi
from
Lexington, KY
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Lucille P. Markey Cancer Center at University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
CCOP - Ochsner
mi
from
New Orleans, LA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
CCOP - Ochsner
mi
from
New Orleans, LA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
St. Agnes Hospital Cancer Center
mi
from
Baltimore, MD
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
St. Agnes Hospital Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Cancer Institute at St. Joseph Medical Center
mi
from
Towson, MD
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Cancer Institute at St. Joseph Medical Center
mi
from
Towson, MD
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Boston University Cancer Research Center
mi
from
Boston, MA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Fairview Southdale Hospital
mi
from
Edina, MN
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Fairview Southdale Hospital
mi
from
Edina, MN
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
mi
from
Minneapolis, MN
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
NYU Cancer Institute at New York University Medical Center
mi
from
New York, NY
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
NYU Cancer Institute at New York University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/23/2018
Adams Cancer Center
mi
from
Gettysburg, PA
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/23/2018
Adams Cancer Center
mi
from
Gettysburg, PA
Click here to add this to my saved trials